SomaLogic, a Boulder, Colorado-based biomarker discovery and clinical diagnostics company, is expected to go public via a merger with a special purpose acquisition company (SPAC). We'll update this page as new information becomes available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $1.73 - $2.91 |
| 50-day moving average | $2.43 |
| 200-day moving average | $2.45 |
| Wall St. target price | $3.93 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.69 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2024-01-25
| 1 week (2024-07-16) | nan% |
|---|---|
| 1 month (2024-06-23) | nan% |
| 3 months (2024-04-23) | nan% |
| 6 months (2024-01-25) | 0 |
| 1 year (2023-07-27) | -100.00% |
|---|---|
| 2 years (2022-07-27) | -100.00% |
| 3 years (2021-07-27) | 11.25 |
| 5 years (2019-07-23) | N/A |
| Revenue TTM | $81.7 million |
|---|---|
| Gross profit TTM | $-11,271,000 |
| Return on assets TTM | -14.17% |
| Return on equity TTM | -23.72% |
| Profit margin | -159.54% |
| Book value | $2.63 |
| Market Capitalization | $396.2 million |
TTM: trailing 12 months
We're not expecting SomaLogic to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, SomaLogic's shares have ranged in value from as little as $1.73 up to $2.91. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SomaLogic's is 1.639. This would suggest that SomaLogic's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put SomaLogic's beta into context you can compare it against those of similar companies.
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.